F16.94
Hallucinogen use, unspecified with hallucinogen-induced mood disorder
Clinical Classification Guidelines
Inclusion Terms
- Other hallucinogen induced bipolar or related disorder, without use disorder
- Other hallucinogen induced depressive disorder, without use disorder
- Phencyclidine induced bipolar or related disorder, without use disorder
- Phencyclidine induced depressive disorder, without use disorder
Medical Intelligence & Overview
ICD-10 code F16.94 pertains to instances where individuals have used hallucinogens and subsequently experience mood disorders triggered directly by these substances. Unlike substance use disorders characterized by dependency, this code specifically addresses mood disturbances caused by hallucinogen use, without an ongoing pattern of abuse or addiction. Conditions under this classification include various forms of bipolar and depressive episodes that are induced by the effects of hallucinogenic substances, such as phencyclidine (PCP) and other hallucinogens.
Causes & Symptoms
Clinical Causes: Use of hallucinogenic substances like LSD, psilocybin, mescaline, or PCP High doses of hallucinogens leading to altered mental states Using hallucinogens in settings that may trigger mood instability Pre-existing mood or psychiatric disorders that can be exacerbated by substance use
Key Symptoms: Mood swings, including episodes of elevated mood or depression Hallucinations or perceptual disturbances Confusion and disorientation Anxiety or paranoia Depressive episodes characterized by feelings of hopelessness or worthlessness Episodes of irritability or agitation Alterations in sleep patterns, such as insomnia or hypersomnia Changes in energy levels, either increased or decreased
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive psychiatric assessment, review of the patient's history of hallucinogen use, and observation of mood symptoms. It may include mental status examinations and laboratory tests to rule out other causes. The clinician will evaluate whether the mood disorder is directly linked to recent hallucinogen use, considering the timing and severity of symptoms in relation to substance intake.
Treatment Protocols: Management typically includes supportive care, psychological therapies, and sometimes medication to stabilize mood. The primary focus is on addressing the mood disorder triggered by hallucinogen use, with treatment plans tailored to individual needs. Substance discontinuation and monitoring are crucial, alongside interventions aimed at mood stabilization. In some cases, hospitalization may be necessary if symptoms are severe.
Clinical Advice & FAQs
Billing Guidance
Is F16.94 a billable ICD-10 code?
Yes, F16.94 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.94?
Clinical documentation must specify the nature of Hallucinogen use, unspecified with hallucinogen-induced mood disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference